We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ProQR Therapeutics NV | NASDAQ:PRQR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.02 | 1.01% | 2.01 | 1.96 | 2.03 | 2.05 | 1.97 | 1.99 | 215,686 | 00:40:09 |
|
The Netherlands
|
| |
Not applicable
|
|
|
(State or other Jurisdiction of
Incorporation or Organization) |
| |
(I.R.S. Employer
Identification No.) |
|
|
Mitchell S. Bloom, Esq.
Danielle M. Lauzon, Esq. James Xu, Esq. Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 (617) 570-1000 |
| |
Smital Shah, Chief Business
and Financial Officer ProQR Therapeutics N.V. Zernikedreef 9 2333 CK Leiden The Netherlands +31 88 166 7000 |
|
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 4 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 16 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 21 | | |
| | |
As of September 30,
2021 |
| |||
| | |
(€ in thousands,
except share and per share data) |
| |||
Cash and cash equivalents
|
| | | € | 156,141 | | |
Total debt: | | | | | | | |
Lease liability
|
| | | | 15,109 | | |
Borrowings
|
| | | | 17,513 | | |
Total debt
|
| | | | 32,622 | | |
Equity: | | | | | | | |
Equity attributable to owners of the Company
|
| | | | 128,606 | | |
Non-controlling interests
|
| | | | (585) | | |
Total equity
|
| | | | 128,021 | | |
Total capitalization
|
| | | € | 160,643 | | |
Name of Selling Shareholder
|
| |
Number of
Ordinary Shares Owned Prior to Offering |
| |
Maximum
Number of Ordinary Shares to be Sold Pursuant to this Prospectus |
| |
Number of
Ordinary Shares Owned After Offering |
| |
Percentage of
Ordinary Shares Owned After Offering (to the extent greater than 1%) |
| ||||||||||||
Pontifax Medison Finance (Israel) L.P.(1)
|
| | | | 569,603(2) | | | | | | 569,603 | | | | | | — | | | | | | — | | |
Pontifax Medison Finance (Cayman) L.P.(3)
|
| | | | 244,891(4) | | | | | | 244,891 | | | | | | — | | | | | | — | | |
Kreos Capital VI (UK) Limited(5)
|
| | | | 1,705,030(6) | | | | | | 1,705,030 | | | | | | — | | | | | | — | | |
Kreos Capital VI (Expert Fund) L.P. (7)
|
| | | | 195,457(8) | | | | | | 195,457 | | | | | | — | | | | | | — | | |
Kreos Capital 2020 Opportunity (UK) Limited(9)
|
| | | | 852,515(10) | | | | | | 852,515 | | | | | | — | | | | | | — | | |
Kreos Capital 2020 Opportunity L.P.(11)
|
| | | | 97,728(12) | | | | | | 97,728 | | | | | | — | | | | | | — | | |
|
SEC registration fee
|
| | | $ | 4,056.16 | | |
|
Legal fees and expenses
|
| | | | * | | |
|
Printing expenses
|
| | | | * | | |
|
Accountants’ fees and expenses
|
| | | | * | | |
|
Miscellaneous expenses
|
| | | | * | | |
|
Total
|
| | | $ | * | | |
|
SIGNATURES
|
| |
TITLE
|
| |
DATE
|
|
|
/s/ Daniel de Boer
Daniel de Boer
|
| |
Chief Executive Officer and Director, Management Board
(Principal Executive Officer) |
| |
March 1, 2022
|
|
|
/s/ Smital Shah
Smital Shah
|
| |
Chief Business and Financial Officer
(Principal Financial and Accounting Officer) |
| |
March 1, 2022
|
|
|
/s/ Dinko Valerio
Dinko Valerio
|
| |
Chairman, Supervisory Board
|
| |
March 1, 2022
|
|
|
/s/ Antoine Benjamin Papiernik
Antoine Benjamin Papiernik
|
| |
Director, Supervisory Board
|
| |
March 1, 2022
|
|
|
/s/ James Shannon
James Shannon
|
| |
Director, Supervisory Board
|
| |
March 1, 2022
|
|
|
/s/ Alison Lawton
Alison Lawton
|
| |
Director, Supervisory Board
|
| |
March 1, 2022
|
|
|
/s/ Bart Filius
Bart Filius
|
| |
Director, Supervisory Board
|
| |
March 1, 2022
|
|
|
By:
/s/ Smital Shah
|
| |
March 1, 2022
|
|
|
Name:
Smital Shah
|
| |
1 Year ProQR Therapeutics NV Chart |
1 Month ProQR Therapeutics NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions